FKBP immunophilin patents for neurological disorders

被引：13

作者：

Babine, RE ^{[1
]}

Villafranca, JE

Gold, BG

机构：

[1] Recovexx Pharmaceut Inc, San Diego, CA 92103 USA

[2] Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97239 USA

[3] Oregon Hlth Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97239 USA

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 2005年 / 15卷 / 05期

关键词：

FK-506; FKBP; FKBP-12; FKBP-52; immunophilin; neurodegenerative disease; tacrolimus; rapamycin;

D O I：

10.1517/13543776.15.5.555

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Immunophilins are a family of binding proteins that are highly conserved in nature and mediate the actions of immunosuppressant drugs. The FK-506-binding protein (FKBP) subclass of immunophilin bind FK-506 and rapamycin and are of particular interest due to their potent neurotrophic activity. Here, the patent literature covering the structures of novel non-immunosuppressant derivatives of FK-506 and rapamycin, and their claims pertaining to their potential use for the treatment of neurological disorders, are reviewed.

引用

收藏

页码：555 / 573

页数：19

相关论文

共 106 条

[11] Use of parallel-synthesis combinatorial libraries for rapid identification of potent FKBP12 inhibitors [J].

Choi, C ;

Li, JH ;

Vaal, M ;

Thomas, C ;

Limburg, D ;

Wu, YQ ;

Chen, Y ;

Soni, R ;

Scott, C ;

Ross, DT ;

Guo, H ;

Howorth, P ;

Valentine, H ;

Liang, S ;

Spicer, D ;

Fuller, M ;

Steiner, J ;

Hamilton, GS .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (10) :1421-1428

[12]

Cooper M. E., 1994, Patent No. [US5376663, 5376663]

[13] Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease [J].

Costantini, LC ;

Cole, D ;

Isacson, O .

EUROPEAN JOURNAL OF NEUROSCIENCE, 2001, 13 (06) :1085-1092

[14] Structure-based design of novel, urea-containing FKBP12 inhibitors [J].

Dragovich, PS ;

Barker, JE ;

French, J ;

Imbacuan, M ;

Kalish, VJ ;

Kissinger, CR ;

Knighton, DR ;

Lewis, CT ;

Moomaw, EW ;

Parge, HE ;

Pelletier, LAK ;

Prins, TJ ;

Showalter, RE ;

Tatlock, JH ;

Tucker, KD ;

Villafranca, JE .

JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (09) :1872-1884

[15] Human hand allograft: report on first 6 months [J].

Dubernard, JM ;

Owen, E ;

Herzberg, G ;

Lanzetta, M ;

Martin, X ;

Kapila, H ;

Dawahra, M ;

Hakim, NS .

LANCET, 1999, 353 (9161) :1315-1320

[16] 2-aryl-2,2-difluoroacetamide FKBP12 ligands: Synthesis and X-ray structural studies [J].

Dubowchik, GM ;

Vrudhula, VM ;

Dasgupta, B ;

Ditta, J ;

Chen, T ;

Sheriff, S ;

Sipman, K ;

Witmer, M ;

Tredup, J ;

Vyas, DM ;

Verdoorn, TA ;

Bollini, S ;

Vinitsky, A .

ORGANIC LETTERS, 2001, 3 (25) :3987-3990

[17]

FUJISAWA PHARM CO, 2001, Patent No. 0105385

[18]

FUJISAWA PHARM CO, 2002, Patent No. 02053159

[19] Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders [J].

Gold, BG .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (10) :2331-2342

[20] Oral administration of a nonimmunosuppressant FKBP-12 ligand speeds nerve regeneration [J].

Gold, BG ;

Zeleny-Pooley, M ;

Chaturvedi, P ;

Wang, MS .

NEUROREPORT, 1998, 9 (03) :553-558

← 1 2 3 4 5 6 7 8 9 10 →